MEDICOVER AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 194.2 SEK | -0.51% |
|
+2.75% | +29.38% |
| Apr. 29 | Nordic Shares Rose Monday; Ratos Series A Climbed Highest | DJ |
| Apr. 26 | Nordic Shares Closed Up Friday; Medicover Series B Climbed Highest | DJ |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 56% by 2026.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company does not generate enough profits, which is an alarming weak point.
- The company is in debt and has limited leeway for investment
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 1104.88 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +29.38% | 2.73B | B+ | ||
| +20.09% | 84.56B | C+ | ||
| -27.30% | 72.41B | B- | ||
| +2.04% | 27.73B | C+ | ||
| -9.00% | 17.75B | B | ||
| -1.14% | 17.11B | A- | ||
| +4.56% | 16.03B | A- | ||
| +69.72% | 13.07B | C- | ||
| +6.66% | 12.91B | A- | ||
| +73.30% | 12.55B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- MCOV B Stock
- Ratings Medicover AB
